Annexon Inc. (NASDAQ: ANNX) announced it has completed enrollment in its pivotal Phase 3 ARCHER II trial of vonaprument for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE